Cerevance’s First-In-Class Parkinson’s Candidate Shows Phase II Promise
CEO Predicts Annual Revenues Up To $1bn
Promising results from a small Phase II study will now propel the company’s CVN424 into pivotal trials, though its optimum dose is still unclear.
You may also be interested in...
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.